The first digital pill will carry a price tag of $1,650 per month and soon be rolled out commercially to the first patients: people with mental illness covered by Medicaid, likely in regions including Florida and Virginia.

The pill, sold by the drug maker Otsuka as Abilify MyCite, is embedded with a sensor that can alert a patient’s physician or caregiver after it’s been swallowed. Approved last November by the Food and Drug Administration for patients with schizophrenia and bipolar disorder, it’s a high-tech upgrade to the antipsychotic drug Abilify, which was first approved 16 years ago and has now gone generic.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy